In xenograft tumor model, mice with oridonin treatment also showed decreased level of BCR-ABL protein in the tumor samples compared to those from vehicle-treated mice (Fig. 1d), indicating that oridonin could be a novel BCR-ABL-targeted agent. Here, ABL1 is linked to neoplasm.